Vigabatrin-associated visual field loss.

@article{Fecarotta2012VigabatrinassociatedVF,
  title={Vigabatrin-associated visual field loss.},
  author={Chris Fecarotta and Robert C. Sergott},
  journal={International ophthalmology clinics},
  year={2012},
  volume={52 3},
  pages={
          87-94, xii
        }
}
Vigabatrin is a selective, irreversible g-aminobutyric acid transaminase inhibitor that was synthesized specifically as an antiepileptic medication in the 1980s and 1990s. It is used as adjunctive therapy for adult patients with refractory complex partial seizures and as monotherapy for infants with infantile spasms (West syndrome). A recent Cochrane Database review of 11 prospective studies of vigabatrin versus placebo for patients with refractory partial seizures illustrated that vigabatrin… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

Vigabatrin: Lessons Learned From the United States Experience.

  • Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES